XML 32 R23.htm IDEA: XBRL DOCUMENT v3.26.1
Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies - Summary of Significant Expense Categories Reviewed By CODM (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Research and development expenses:    
Efzofitimod expenses $ 3,535 $ 8,804
Preclinical development and other shared research and development expenses 3,355 2,560
Non-cash expenses (depreciation and stock-based compensation) 427 450
Total research and development expenses 7,317 11,814
General and administrative expenses:    
Other general and administrative expenses 3,076 3,064
Non-cash expenses (depreciation and stock-based compensation) 1,043 895
Total general and administrative expenses 4,119 3,959
Other segment items 644 892
Consolidated net loss $ (10,792) $ (14,881)